Introduction {#Sec1}
============

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is characterized by abdominal pain, recurrent episodes of rectal bleeding, and greater-than-normal stool frequency \[[@CR1], [@CR2]\]. In the United States (US), the estimated prevalence of UC is 263 per 100,000 adults, and epidemiologic data suggest that the disease has become increasingly prevalent during the past decade \[[@CR3]\]. Although slightly more than half of patients with UC have high initial disease activity followed by remission or mild disease severity, \>40% of patients may have chronic continuous or intermittent symptoms of high disease activity \[[@CR4]\]. Progression of UC may include proximal extension of the disease, colonic dysmotility, anorectal dysfunction, and an increased risk of colorectal cancer \[[@CR5], [@CR6]\]. The disease may adversely affect patients' daily activities and quality of life (QoL), and patients with UC have higher rates of sick leave and disability than do individuals in the general population \[[@CR2], [@CR7]\].

A variety of misperceptions about UC may influence management strategies and limit opportunities for improving patient outcomes; for example, UC is commonly regarded as more benign than Crohn's disease (CD) \[[@CR1]\]. However, despite continuing advances in the treatment of UC, approximately half of patients do not achieve sustained clinical remission \[[@CR1]\], and approximately 15% of patients undergo a colectomy within 20 years after UC diagnosis \[[@CR8]\]. Although colectomy is widely seen as a definitive treatment option for UC, the procedure often leads to complications, such as acute or chronic pouchitis or the risk of infertility \[[@CR1], [@CR9]\]. Results from a recent systematic review of 99 studies (conducted between 1976 and 2014 and involving \>180,000 patients) suggest that approximately one-third of patients who undergo colorectal surgery for UC have long-term or late-occurring complications \[[@CR9]\].

In this study, we aimed to assess gastroenterologists' attitudes toward and perceptions of UC via a small-scale qualitative phone survey followed by a large-scale, quantitative web-based survey.

Methods {#Sec2}
=======

This survey study was in accordance with the ethical standards of an institutional review board and with the Helsinki Declaration of 1964, as revised in 2013, and consisted of two phases. Phase 1 was a small-scale phone survey, results of which have been reported previously (Table S1 in the supplementary material) \[[@CR10]\] and were used in the development of the phase 2 survey. The phase 2 survey was a large-scale web-based survey of gastroenterologists who provided informed consent and received an honorarium of \$75.00 for being included in the study and were members of the All Global physician panel, an actively managed, double opt-in group of physicians who elect to participate in periodic surveys. All US members of the All Global panel were verified using the American Medical Association database. A total of 15,000 US gastroenterologists from the panel were invited via e-mail to participate. Key inclusion criteria stipulated that participants be board certified in and have a primary specialty of gastroenterology; spend ≥50% of their professional time on direct patient care; spend ≥50% of their professional time in a private practice, clinic, or hospital setting; and treat ≥10 adults with UC per month.

The survey included questions regarding several aspects of UC and its treatment (see online supplementary material for the complete survey). To assess perceptions of UC vs. CD, gastroenterologists were asked to rate their level of agreement with each of four statements on a scale of 1 (strongly disagree) to 7 (strongly agree). Survey participants then rated 11 additional statements in terms of their association with UC or CD (scale: 1, most associated with UC; 4, equally associated with UC and CD; 7, most associated with CD). To evaluate factors used in distinguishing mild from moderate UC, participants selected their top five choices from a list of 17 factors. In addition, respondents were asked to choose any and all items (from a list of 10) that they considered to be defining features of clinical remission in UC.

Given a list of 10 potential treatment goals for UC, participants first rated each goal on a scale of 1 (extremely unimportant) to 7 (extremely important) and then ranked these goals in order of their importance, with 1 being the most important. Respondents also rated the performance of four medication classes (5-aminosalicylic acid \[ASA\] agents, corticosteroids, immunomodulators, and biologics/anti-tumor necrosis factor agents) in achieving each treatment goal using a scale of 1 (very poor) to 5 (very well).

Participants rated the frequency with which they used each medication class (1, never; 5, always) as induction and maintenance therapies for patients with mild, moderate, and severe UC. In addition, for each medication class, respondents indicated the number of weeks that patients with mild, moderate, and severe UC remained on the treatment before it was deemed successful or not. To assess drivers for the initiation of biologic therapy, respondents were asked to select up to five statements (from a list of 17) that might prompt them to prescribe biologic therapy. Finally, participants were asked if they experienced barriers to the use of biologic therapies, and those who answered yes were asked to select all that applied from a list of 12 potential barriers.

All survey responses were summarized with descriptive statistics. Single-sample *t* tests were used to analyze responses to questions about whether statements are more indicative of UC or CD. The frequency at which each type of treatment was used as induction and maintenance therapies was analyzed using a mixed model, and a similar mixed model was used to assess differences in attribute agreement across treatments. A final mixed model was used to analyze differences with respect to the necessary duration of treatment before success (or lack thereof) could be established. All tests of significance were two-tailed.

Results {#Sec3}
=======

Participant Characteristics {#Sec4}
---------------------------

Participants (*N* = 500) in the phase 2 survey were predominantly male gastroenterologists between the ages of 35 and 64 years (Table [1](#Tab1){ref-type="table"}). More than half of respondents were part of a private group practice, and the average time in practice was 16.5 years. Participants reported spending the vast majority of their time on direct patient care, seeing \>300 patients per month on average.Table 1The phase 2 survey participant characteristics (*N* = 500)CharacteristicSex, *n* (%) Male441 (88.2) Female48 (9.6) Not stated11 (2.2)Age, years, *n* (%) \<3529 (5.8) 35--44152 (30.4) 45--54140 (28.0) 55--64135 (27.0) ≥6532 (6.4) Not stated12 (2.4)Practice type, *n* (%) Solo73 (14.6) Single-specialty group250 (50.0) Multispecialty group177 (35.4)Years in practice, mean (SD)16.50 (8.73)Percentage of time allocation, mean (SD) Direct patient care92.54 (10.00) Teaching3.24 (5.37) Conducting research1.97 (5.38) Administration2.17 (3.69) Other activities0.08 (1.03)Type of setting for patient care, *n* (%) Hospital (nonteaching/academic)15 (3.0) Hospital (teaching/academic)122 (24.4) Clinic23 (4.6) Private group practice282 (56.4) Private solo practice58 (11.6)Number of adult patients per month, mean (SD)317.5 (146.3)Diagnosis of adult patients, mean (SD), % of patients UC17.7 (14.7) CD17.2 (15.1) Other, non-IBD60.6 (29.4)UC severity, mean (SD), % of patients Mild41.6 (19.9) Moderate38.4 (14.7) Severe19.95 (12.13)CD severity, mean (SD), % of patients Mild37.2 (20.0) Moderate40.7 (15.4) Severe22.2 (12.7)*CD* Crohn's disease, *IBD* inflammatory bowel disease, *SD* standard deviation, *UC* ulcerative colitis

Perceptions of UC vs. CD {#Sec5}
------------------------

Compared with CD, UC was perceived as easier to diagnose and having better treatment outcomes (Fig. [1](#Fig1){ref-type="fig"}a). Survey respondents prescribed biologics earlier for CD than for UC. CD was perceived as having a greater effect than UC on patients' ability to perform daily activities (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1**a** Association of statements with UC or CD. Rated on a continuous scale from 1 to 7; *lower scores* indicate a greater association with UC; the *dotted line* indicates an equal association between UC and CD; and *higher scores* indicate a greater association with CD. **b** Participant agreement with UC- and CD-related statements. \**P* \< 0.05. *Bars* represent means; and *error bars* represent 95% confidence intervals. *CD* Crohn's disease, *IM* immunomodulatory, *QoL* quality of life, *TNF* tumor necrosis factor, and *UC* ulcerative colitis

Determining UC Severity {#Sec6}
-----------------------

Factors that physicians most commonly used to distinguish between mild and moderate UC included number of stools per day above normal, ulcerations on endoscopy, and rectal bleeding, each cited by \>50% of respondents (Table [2](#Tab2){ref-type="table"}). Less commonly cited factors (cited by \<50% but \>20% of respondents) were anemia, impact on QoL, weight loss, hospitalizations per year, abdominal pain, nocturnal bowel movements, friability on endoscopy, and fever.Table 2Factors used by gastroenterologists to distinguish mild from moderate UC (*N* = 500)ResponseNumber (%) of participants citingNumber of stools per day above normal306 (61.2)Ulcerations on endoscopy278 (55.6)Rectal bleeding272 (54.4)Anemia211 (42.2)Impact on QoL182 (36.4)Weight loss174 (34.8)Hospitalizations per year169 (33.8)Abdominal pain166 (33.2)Nocturnal bowel movements160 (32.0)Friability on endoscopy118 (23.6)Fever117 (23.4)Tenesmus89 (17.8)Urgency79 (15.8)Spontaneous bleeding on endoscopy71 (14.2)Tachycardia48 (9.6)Fecal incontinence31 (6.2)Fecal calprotectin level29 (5.8)*QoL* quality of life, *UC* ulcerative colitis

The top factors used to distinguish mild from moderate UC were also examined on the basis of various practitioner characteristics. No significant differences based on gender, practice setting (private vs. public/other), or practice type (group vs. solo) were noted. However, gastroenterologists aged ≤44 years cited ulcerations on endoscopy as a top factor significantly more often than did those aged ≥45 years (data not shown).

Defining Clinical Remission in UC {#Sec7}
---------------------------------

Improved QoL was among the most often cited defining features of clinical remission, along with normalization of bowel habits, absence of rectal bleeding, return to normal daily activities, and complete mucosal healing (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Defining features of clinical remission among patients with UC, as reported by gastroenterologists (*N* = 500). *CRP* C-reactive protein, *QoL* quality of life, and *UC* ulcerative colitis

UC Treatment Goals and Medication Performance Ratings {#Sec8}
-----------------------------------------------------

Treatment goals that were commonly considered most important by the survey participants included QoL improvement (31.2% of respondents), maintenance of clinical remission (17.4%), and mucosal healing (17.4%). When respondents rated the performance of each medication class in achieving each of these treatment goals, biologics had significantly higher ratings than all other classes (*P* \< 0.05), whereas 5-ASA agents commonly had the lowest ratings (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Performance ratings of medication classes by UC treatment goals. *Scale* *1* very poor; *5* very well. Letters *A*, *B*, *C*, and *D* indicate which medication groups were significantly different from others for each attribute (*P* \< 0.05, a Tukey post hoc adjustment). *Error bars* represent 95% confidence intervals. *Asterisk* indicates not applicable. *ASA* aminosalicylic acid, *QoL* quality of life, and *UC* ulcerative colitis

Medication Use by UC Severity {#Sec9}
-----------------------------

Medication class use by severity of UC was generally consistent with the traditional step-up approach to UC therapy \[[@CR11]--[@CR13]\]. For mild and moderate UC, 5-ASA agents were employed significantly more often than any other class (*P* \< 0.05), regardless of whether they were used for induction or maintenance. For severe UC, corticosteroids were used more often for induction, and biologics were used more often for maintenance than any other medication class (*P* \< 0.05 for both). Unlike use of other medication classes, the use of 5-ASA agents decreased with increased UC severity (*P* \< 0.05 for use in mild vs. moderate, mild vs. severe, and moderate vs. severe UC). However, somewhat unexpectedly, the mean frequency rating for 5-ASA agent use was high for severe UC (induction, 3.06 \[95% confidence interval (CI), 2.97--3.14\]; maintenance, 3.36 \[95% CI, 3.27--3.44\]). For some medication classes, the frequency of use in mild, moderate, and severe UC differed significantly depending on the characteristics of the treating gastroenterologist, including gender, age, practice setting, and practice type (Tables S2 and S3 in the supplementary material).

Duration of Treatment by Medication Class {#Sec10}
-----------------------------------------

Corticosteroids required the shortest duration of use before treatment success (or lack thereof) was determined; immunomodulators required the longest duration (Fig. [4](#Fig4){ref-type="fig"}). The mean duration of 5-ASA use before treatment was deemed unsuccessful was significantly shorter for severe UC than for mild UC (*P* \< 0.05). Conversely, the mean duration of immunomodulator use before establishment of treatment success/lack of success was significantly longer for moderate and severe UC than for mild UC (*P* \< 0.05). For corticosteroids and biologics, the duration of use before treatment success designation was similar across mild, moderate, and severe UC.Fig. 4Time (weeks) a patient with UC must receive therapy before it is deemed successful or not by medication class. *Bars* represent mean values. Letters *A*, *B*, *C*, and *D* indicate which medication classes were significantly different from other classes within each level of UC severity (*P* \< 0.05 using a Tukey post hoc adjustment). *Error bars* represent 95% confidence intervals. *ASA* aminosalicylic acid and *UC* ulcerative colitis

Drivers for Use of Biologic Therapy {#Sec11}
-----------------------------------

The most common drivers for initiation of biologic therapy in patients with moderate-to-severe UC included the development of steroid refractoriness (66.8%) and steroid dependency (65.8%), increases in the number of hospitalizations for UC (62.2%), and decreases in patients' ability to perform daily activities (56.0%). Laboratory measures, including C-reactive protein levels, were not strong drivers for initiation of biologic therapy.

Barriers to Use of Biologic Therapy {#Sec12}
-----------------------------------

Of the 500 survey respondents, 219 (43.8%) reported that they have experienced barriers to prescribing biologics for UC. The most commonly cited barriers included patient insurance restrictions (79.0%), out-of-pocket cost for patients (71.7%), and patient and physician concerns about side effects (57.1% and 50.7%, respectively).

Discussion {#Sec13}
==========

These survey results highlight common perceptions among practicing physicians, including the idea that UC is relatively benign and less burdensome and easier to diagnose and treat than CD. However, results from other recent surveys suggest that despite treatment, many patients feel that UC disrupts their lives and relationships and is associated with substantial physical and psychological burdens \[[@CR14]--[@CR17]\]. Compared with patients, gastroenterologists who treat UC may underestimate the physical and psychological impacts of the disease as well as the disruptive effects of symptoms on day-to-day life while simultaneously overestimating disease control \[[@CR18]\]. In addition, findings from a recent French survey study suggest that treatment with anti-tumor necrosis factor agents was significantly less common in patients with UC than in those with CD and that despite recent increases in available biologic treatment options, disease activity persists in many patients \[[@CR19]\].

The perceptions about UC highlighted herein may ultimately lead to suboptimal management approaches. In the current survey, UC steroid refractoriness and steroid dependency were the most commonly cited drivers for the initiation of biologic therapy, which implies that biologics are used relatively late in the disease course, consistent with the traditional step-up approach to therapy. Meanwhile, the recent literature suggests that treatment goals and therapeutic approaches for UC are evolving \[[@CR11], [@CR13], [@CR20]--[@CR23]\]. The premise behind earlier use of more potent therapies is the potential for rapid induction of steroid-free remission and promotion of mucosal healing, which may modify the natural history of UC \[[@CR23]\].

As an alternative approach, some authors have suggested that structured treatment algorithms with specific time limits for evaluation of therapeutic success would be useful in guiding therapeutic decisions and achieving treatment goals \[[@CR23]\]. The recently published Ulcerative Colitis Care Pathway considers not only disease activity but also risk stratification to provide a pragmatic management tool for clinicians \[[@CR24]\]. Treat-to-target strategies have also emerged, wherein treatment algorithms are geared toward a specific, well-defined target or targets, such as mucosal healing, histologic healing, or deep remission \[[@CR11], [@CR13], [@CR21], [@CR25]\]. In cases where a link between the pharmacokinetic and pharmacodynamic effects of a biologic agent has been well established, therapeutic drug monitoring with dosage adjustment to achieve a serum trough drug concentration target helps to improve outcomes and reduce costs \[[@CR13], [@CR21], [@CR25]\]. Furthermore, assessment for the presence of anti-drug antibodies along with drug concentration monitoring could help guide treatment decisions \[[@CR13], [@CR26]\].

Several limitations of this study should be noted. First, as in any survey study and particularly in the context of honoraria provided for survey completion, the physician-reported data described herein may have been affected by recall bias, and there was no independent confirmation of data (e.g., frequency of medication use) from medical records. Survey participants may also have had characteristics that differ from those who chose not to participate; thus, results may not be generalizable to the overall gastroenterology population. In addition, the survey did not include questions about certain practice dynamics (e.g., typical frequency and duration of appointments, involvement of nurse practitioners or physician assistants in patients' care), which could have yielded useful insight on perceptions of UC. Finally, the survey did not allow participants to specify whether medications were used as monotherapy or as part of polytherapy, thus hindering the interpretation of medication use and duration of use data.

Despite these limitations, this study had numerous strengths, including its 2-phase design, wherein results from a small preliminary phone survey were used to inform the development of the large-scale, web-based phase 2 survey described here. Survey participants were 500 experienced and currently practicing gastroenterologists who treat at least 10 patients with UC per month on average and spend \>50% of their professional time on direct patient care. Thus, these data represent a robust sample of physicians with extensive clinical experience in treating patients with UC.

The current survey study provides valuable information regarding UC from the perspective of gastroenterologists. Clinicians' perceptions of UC may influence their treatment goals and therapeutic decisions, possibly limiting opportunities for better outcomes with earlier use of therapies that may be effective. An increased awareness of such perceptions is an important step toward a better overall understanding of UC and, ultimately, toward improved management aligned with treatment goals.
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